Phase I Post-Transplant Maintenance with Tagraxofusp in CD123+ Myeloid Disorders

The University of Virginia is investigating escalating doses of tagraxofusp—a diphtheria toxin-IL3 fusion protein—as maintenance therapy post-allogeneic HCT in patients with CD123+ AML, CMML, and myelofibrosis. Participants receive up to nine cycles with interim bone marrow evaluations to gauge efficacy and safety in relapse prevention.